GlaxoSmithKline Plc’s new chief executive plans to slim down the company’s pipeline, reduce costs and focus on respiratory medicines and treatments for HIV and infectious disease as part of a sweeping review of the company’s priorities. ---Subscribe to MedNous to access this article--- Company News
